Enterobacteriaceae Clinical Trial
Official title:
Prevalence of Clinical Strains of Enterobacteria With Reduced Susceptibility to Carbapenems in the North-West Region of France
Enterobacteria constitute a family of Gram negative bacilli of the gastrointestinal flora.
These micro-organisms are frequently responsible for nosocomial or community-acquired
infections, for which treatment is essentially based on the use of beta-lactam antibiotics.
This class of antibiotics comprises penicillins, cephalosporins, monobactams and
carbapenems. Carbapenems have the advantage of possessing a broad antibacterial spectrum and
the capacity to resist the hydrolytic action of a large number of beta-lactamases,
widespread inactivating enzymes.
However, new enzymes, called carbapenemases, able to confer resistance to carbapenems either
alone or in combination with additional resistance mechanisms such as loss of membrane
permeability or overexpression of efflux systems, are currently emerging all over the world.
Carbapenemases represent a major public health problem because of the risk of therapeutic
impasse and their high epidemic potential.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02367339 -
Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff
|
N/A |